Berberine Promotes Glucose Consumption Independently of AMP-Activated Protein Kinase Activation

Miao Xu1*, Yuanyuan Xiao1, Jun Yin1*, Wolin Hou1, Xueying Yu1, Li Shen2, Fang Liu1, Li Wei1*, Weiping Jia1

1 Shanghai Clinical Center for Diabetes, Shanghai Clinical Center for Metabolic Diseases, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, 2 Department of Clinical Nutrition, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Abstract

Berberine is a plant alkaloid with anti-diabetic action. Activation of AMP-activated protein kinase (AMPK) pathway has been proposed as mechanism for berberine’s action. This study aimed to examine whether AMPK activation was necessary for berberine’s glucose-lowering effect. We found that in HepG2 hepatocytes and C2C12 myotubes, berberine significantly increased glucose consumption and lactate release in a dose-dependent manner. AMPK and acetyl coenzyme A synthetase (ACC) phosphorylation were stimulated by 20 μmol/L berberine. Nevertheless, berberine was still effective on stimulating glucose utilization and lactate production, when the AMPK activation was blocked by (1) inhibition of AMPK activity by Compound C, (2) suppression of AMPKα expression by siRNA, and (3) blockade of AMPK pathway by adenoviruses containing dominant-negative forms of AMPKα1/α2. To test the effect of berberine on oxygen consumption, extracellular flux analysis was performed in Seahorse XF24 analyzer. The activity of respiratory chain complex I was almost fully blocked in C2C12 myotubes by berberine. Metformin, as a positive control, showed similar effects as berberine. These results suggest that berberine and metformin promote glucose metabolism by stimulating glycolysis, which probably results from inhibition of mitochondrial respiratory chain complex I, independent of AMPK activation.

Citation: Xu M, Xiao Y, Yin J, Hou W, Yu X, et al. (2014) Berberine Promotes Glucose Consumption Independently of AMP-Activated Protein Kinase Activation. PLoS ONE 9(7): e103702. doi:10.1371/journal.pone.0103702

Editor: Hossein Ardehali, Northwestern University, United States of America

Received December 1, 2013; Accepted July 5, 2014; Published July 29, 2014

Copyright: © 2014 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by NSFC fund (31171128) and Shanghai Pujiang Project (11PJ1407700) to Jun Yin, and NSFC fund (81200655) to Li Shen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: yinjun@sjtu.edu.cn (JY); weili63@hotmail.com (LW)
† These authors contributed equally to this work.

Introduction

Berberine, a plant isoquinoline alkaloid, is used as an over-the-counter drug in China to treat infectious diarrhea. The Chinese name of berberine is Huangliansu, which means the element of Rhizoma Coptidis. Rhizoma Coptidis is a popular traditional Chinese herb used for treatment of inflammation and diabetes, and contains 5.2%–7.7% of berberine. The anti-diabetes activity of Rhizoma Coptidis is documented as early as 1500 years ago. However, Rhizoma Coptidis was usually used to treat infection or inflammation since diabetes was not popular in ancient time [1,2].

The beneficial effects of berberine on metabolism are pleiotropic. In folk medicine of China, berberine is used to treat diabetes, obesity and non-alcoholic fatty liver disease [3–7]. In addition, berberine is also reported to alleviate dyslipidemia and cardiovascular diseases [8–11]. A variety of molecular mechanisms were proposed for the anti-diabetic effect of berberine, such as AMPK activation [12,13], inhibition of PPARγ and C/EBPα function [14,15], antioxidant [16], inhibition of aldose reductase and inhibitory activities on MAPK [17–19]. Among them, AMPK activation is considered as the major mechanism. AMPK is a highly conserved sensor of cellular energy status that exists in almost all eukaryotes; phosphorylation of Thr-172 is used as a biomarker of AMPK activation, which can be enhanced by berberine and metformin. Once activated, AMPK promotes catabolic processes (glycolysis, fatty acid oxidation, etc.), while turning off anabolic pathway (glycogen, cholesterol and protein synthesis, etc.) [20]. Thus, AMPK pathway is one of the most important drug targets for metabolism regulation.

However, our previous study indicated that berberine enhanced glucose metabolism via stimulation of glycolysis, which was related to inhibition of glucose oxidation in mitochondria [21]. Since stimulating glycolysis could be a direct consequence of mitochondrial inhibition, we hypothesize that berberine’s effect on glucose metabolism is related to mitochondrial inhibition, independent of AMPK activation. In this context, we evaluated underlying mechanisms of berberine’s effects on glycolysis and glucose consumption with emphasis on the roles of AMPK and mitochondrial respiratory chain complex I. Metformin, another well-known AMPK activator, was used as a positive control to verify the activation of AMPK in our cellular models. Our results suggest both berberine and metformin promote glucose consumption independently of AMPK activation.
Materials and Methods

Reagents
Berberine was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Metformin was purchased from Shanghai Sangon Biotechnology Corporation (Shanghai, China). Both drugs were dissolved in deH2O, which was used as the vehicle for berberine and metformin. Compound C was purchased from Merck KGaA (Darmstadt, Germany) and dissolved in DMSO, which was used as the vehicle for compound C. Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and other culture reagents were purchased from Gibco Life Technologies (Grand Island, NY). Rotenone, sodium pyruvate, GluhaMax-1 and other chemical reagents were purchased from Sigma Chemicals (St Louis, MO).

Cells
The human hepatoma cell line HepG2 and mouse skeletal myoblast C2C12 were maintained in a 37°C, 5% CO2 incubator and cultured in a growth medium: DMEM supplemented with 10% fetal bovine serum, 10% FBS for 24 h. Then the medium was replaced by differentiation medium: DMEM containing 2% horse serum, 100 units/ml penicillin and 0.1 mg/ml streptomycin for 6 days.

C2C12 myoblasts were seeded into 12-well plates in DMEM with glucose DMEM for C2C12 cells). For differentiation of myotubes, 100 units/ml penicillin and 0.1 mg/ml streptomycin (low-glucose DMEM for HepG2 cells, and high-glucose DMEM for C2C12 cells). For differentiation of myotubes, C2C12 myoblasts were seeded into 12-well plates in DMEM with 10% FBS for 24 h. Then the medium was replaced by differentiation medium: DMEM containing 2% horse serum, 100 units/ml penicillin and 0.1 mg/ml streptomycin for 6 days. The medium was refreshed every 48 h.

Glucose consumption
The cells were cultured in 96-well plates and treated with berberine or metformin at various concentrations in FBS-free DMEM (15 mmol/L D-glucose) supplemented with 0.25% BSA for 24 h. The glucose concentration in the medium was determined by the glucose oxidase method. The amount of glucose consumption was calculated by subtracting the glucose concentration of cells treated with berberine or metformin from the cells treated with vehicle [22,23].

LDH cytotoxicity assay
The percentage of living cells was determined using the Lactate Dehydrogenase (LDH) Cytotoxicity Assay Kit (Beyotime Institute of Biotechnology, Jiangsu, China). In brief, HepG2 hepatocytes and C2C12 myotubes were cultured in 96-well plates. After berberine or metformin treatment for 24 h in DMEM supplemented with 0.25% BSA, LDH was measured in medium and cell extracts according to the manufacturer’s instruction.

RNA interference
One day before transfection, HepG2 cells were placed into 24-well plates. When cell densities reached 50% confluent, they were transfected with siRNA directed against AMPKα1/α2 (sc-45312; Santa Cruz, CA, USA) or scrambled siRNA (sc-37007; Santa Cruz, CA, USA) as a control. Briefly, cells were transfected with 30 pmol/well siRNA via Lipofectamine 2000 Transfection Reagent (11668; Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

Adenovirus Infection
Recombinant adenoviruses expressing dominant negative forms of AMPK, AMPKα1 (D159A) and AMPKα2 (K45R) (α1/α2-DN), were gifts from Dr. Jia Li at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The α1/α2-DN were used to block AMPK activity as previously described [24,25]. In brief, HepG2 cells were infected with adenovirus expressing control GFP reporter protein or dominant site mutagenesis AMPKα1/α2, hereinafter referred to as DN-AMPK, for 5–6 h and treated with berberine or metformin for 24 h after infection.

Western blot
Cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed with lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM EDTA, 10 μg/ml leupeptin, 1 mM PMSF, and phosphatase inhibitor cocktail; pH 7.4). The extracted protein (35 μg) was boiled for 5 min, subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Then the separated proteins were transferred onto a nitrocellulose membrane. After blocked with 5% skim milk in the TBST buffer for 1 h, the membrane was incubated with primary antibody at 4°C overnight. Antibodies to AMPK, acetyl coenzyme A synthetase (ACC), phospho-AMPK (Thr172), β-actin and phospho-ACC (Ser-79) were purchased from Cell Signaling Technology (Danvers, MA). The HRP-conjugated secondary antibodies (Promega Corporation, Madison, USA) were used with chemiluminescence reagent (Thermo Fisher Scientific Inc., Rockford, USA) for generation of the light signal; Gel-Pro Analyzer 4.0 was used to quantify the Western signals.

Determination of lactate content
The cells were cultured in 96-well plates and treated with berberine or metformin in DMEM supplemented with 0.25% BSA for 24 h. The lactate concentration in the medium was measured with a lactate reagent kit (Shanghai Juchuang Biotechnology Corporation, Shanghai, China).

Extracellular flux (XF) analysis
C2C12 myoblasts were seeded in XF 24-well cell culture microplates (Seahorse biosciences, North Billerica, MA) at 1.25×10⁴ cells/well in 250 μl of growth medium and placed in a 37°C incubator with 5% CO2. Once the cells achieved confluence, differentiation medium was used to induce the myotube differentiation. The medium was refreshed every other day. After 6 days, C2C12 myotubes were treated with 20 μmol/L berberine or 5 mmol/L metformin for 24 h, followed by XF bioenergetic assay. Assays were initiated by replacing the medium with 675 μl of assay medium [8.3 g/l DMEM Base, 1.85 g/l NaCl, 2 mM GluhaMax-1, 1 mM sodium pyruvate, 15 mM D-glucose, 20 mM HEPES and 15 mg of Phenol Red; pH 7.4] prewarmed to 37°C. Cells were incubated at 37°C without CO2 for 60 min to allow cells to preequilibrate with the assay medium before the first measurement.

After the equilibration period, cells were subjected to three baseline measurements, followed by injection of the following reagents: 1 μM oligomycin, an inhibitor of ATP synthesis was used to distinguish O2 consumption devoted to ATP synthesis; 1 μM FCCP (Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone), an uncoupling agent was added to measure uncoupled respiration; 1 μM rotenone, a complex I inhibitor was used to assay complex I-linked respiration [26,27].

Statistical analysis
Data are presented as means ± SEM form individual experiments. All experiment were performed at least in triplicate.
Student’s t-test or one-way ANOVA (SPSS 17.0) was used in statistical analysis of the data, with \( P < 0.05 \) considered significant.

**Results**

**Berberine inhibited respiratory chain complex I and reduced ATP synthesis in C2C12 myotubes**

Extracellular flux analysis was performed to assess the mitochondrial respiration in C2C12 myotubes. As shown in Fig. 1A, treatment of berberine or metformin for 24 hours significantly decreased the basal oxygen consumption rates (OCR). The decrease in OCR resulted from blocking ATP synthetase by oligomycin was used as a marker of ATP synthesis. Compared with control, berberine or metformin significantly reduced ATP synthesis in C2C12 myotubes (Fig. 1B). FCCP, a chemical uncoupler of electron transport and oxidative phosphorylation, increased OCR to the maximum. Rotenone inhibited respiratory chain complex I and reduced the OCR to the minimum. The difference in OCR induced by these two compounds was the \( \frac{O_2}{consumption} \) incurred by complex I, and used to evaluate complex I - linked respiration. Complex I - linked respiration was almost abolished with the treatment of berberine or metformin (Fig. 1C). Nevertheless, there was no significant alteration in complex II - linked respiration between control and treatment groups (Fig. S1).

**Berberine had no cytotoxicity**

The data above suggested that berberine or metformin inhibited respiratory chain complex I. It was necessary to know whether these drugs had toxicity in the cells. Thus, LDH cytotoxicity assay was conducted to address this issue. Obviously, in both HepG2 hepatocytes and C2C12 myotubes, neither berberine nor metformin increased LDH release during the exposure duration up to 24 h (Fig. 2). These data suggested that berberine or metformin did not exhibit toxicity in our experimental system.

**Berberine increased lactate release in vitro**

To investigate the effect of berberine on anaerobic respiration, lactate release was measured in HepG2 hepatocytes and C2C12 myotubes. HepG2 cells were incubated for 24 h in the presence or absence of 5, 10, 20 or 40 \( \mu \text{mol/L} \) berberine. Lactate release of HepG2 hepatocytes was increased by berberine in a dose-dependent manner. The concentration of lactate increased by 57.25% to 75.13% (\( P < 0.001 \); Fig. 3A). Incubation with 1 to 10 \( \mu \text{mol/L} \) metformin for 24h, lactate release of HepG2 hepatocytes was increased by 41.0% to 74.8% (\( P < 0.001 \); Fig. 3B). Similar effect was observed in C2C12 myotubes (\( P < 0.01 \) to \( P < 0.001 \); Fig. 3C and D). Lactate is the end product of glycolysis. These data suggested that berberine may induce anaerobic respiration in vitro.

**Berberine improved glucose consumption in vitro**

The data above suggested that berberine affected cellular respiration by inhibiting aerobic respiration and stimulating anaerobic respiration. It was known that glycometabolism was closely related to cellular respiration. To identify the effect of berberine or metformin on glycometabolism, glucose consumption in vitro.
was examined in HepG2 hepatocytes and C2C12 myotubes after 24 h treatment of berberine or metformin. In HepG2 hepatocytes, at concentrations between 5 and 20 μmol/L, berberine increased glucose consumption by 29.91% to 45.91% (P<0.001; Fig. 4A). Metformin increased glucose consumption in a dose-dependent manner. In doses of 1, 2, 5 and 10 mmol/L, the glucose consumption was increased by 12.59% to 41.74% (P<0.001; Fig. 4B). Similar effects of these two drugs were observed in C2C12 myotubes (Fig. 4C and D).

Berberine induced AMPK phosphorylation in HepG2 hepatocytes and C2C12 myotubes
Effects of berberine on AMPK activity were detected in HepG2 hepatocytes and C2C12 myotubes. Significant increases of AMPK and ACC phosphorylation were observed after treatment with 20 μmol/L berberine or 10 mmol/L metformin for 24 h. Berberine increased phosphorylation level of AMPK (Thr172) and ACC (Ser79) by 2.0- and 2.8-fold greater than control in hepatocytes, by 2.4- and 2.8-fold higher than control in myotubes, respectively (Fig. 5 C and D).

Berberine-stimulated glucose consumption and lactate release were not blocked by compound C
To determine whether berberine-stimulated glucose consumption and lactate release involved activation of AMPK pathway, the effect of compound C, an AMPK inhibitor, on berberine-stimulated glucose consumption and lactate release were measured. HepG2 hepatocytes and C2C12 myotubes were incubated for 30 min with 10 μmol/L compound C, following treatment with berberine or metformin for 24 h. As shown in Fig. 6A, compound C fully blocked berberine or metformin-induced ACC phosphorylation, and decreased phosphorylation level of AMPK, suggesting it had inhibited AMPK activity in HepG2 hepatocytes and C2C12 myotubes. With treatment of compound C, berberine and metformin still increased glucose consumption by 78.6% and 91.3% (P<0.001, P<0.001) in HepG2 cells (Fig. 6B), 71.6% and 60.3% (P<0.001, P<0.001) in C2C12 cells, respectively (Fig. 6C).

Berberine-stimulated glucose consumption and lactate release were not blocked upon AMPKα1/α2 silencing in HepG2 hepatocytes
To further prove the effect of AMPK on glucose-lowering action of berberine, AMPKα1/α2 siRNA was used to inhibit the expression and activation of AMPKα in HepG2 hepatocytes. As shown in Fig. 7A and B, compared with scrambled siRNA, AMPKα1/α2 siRNA significantly decreased the expression of AMPKα (P<0.001), meanwhile berberine or metformin-induced AMPKα phosphorylation was also blocked. It was similar to compound C study. Compared with control, berberine or metformin significantly increased glucose consumption and lactate release in all three groups. Although the levels of glucose consumption and lactate concentration in siRNA transfected HepG2 hepatocytes were slightly below the blank control, there were no significant differences in berberine or metformin induced glucose consumption and lactate release between scrambled siRNA and AMPKα1/α2 siRNA transfection (Fig. 7C and D). The data indicated that AMPKα1/α2 silencing did not reduce the glucose-lowering effect of berberine.
Discussion

In the late 1990s, as a result of screening novel hypoglycemic agents from active components of traditional Chinese herbs, we found berberine, a main component of an ancient Chinese herb *Coptis chinensis* French, had a significant glucose-lowering effect in HepG2 cells [28,29]. We further compared berberine with other oral hypoglycemic agents and found that the effect of berberine was independent of insulin, which was quite different from that of troglitazone, the first thiazolidinedione used in clinical setting [22,30]. Based on these findings, we conducted one of the first clinical trials to investigate the efficacy of berberine on diabetes. In newly diagnosed type 2 diabetic patients, hemoglobin A1c was decreased from ~9.5% to ~7.5% after berberine treatment for 3 months. The study indicated that berberine was a potent oral hypoglycemic agent with beneficial effects on lipid metabolism [4].

Our current study is to identify whether AMPK is necessary for glucose consumption and glycolysis induced by berberine or metformin. Although Jeong et al. found that the effects of berberine on proinflammatory responses in macrophages were AMPK dependent [32], there is no reported study to investigate if AMPK was essential for the glucose-lowering effect of berberine. In current study, inactivation of AMPK via siRNA, compound C, or DN-AMPK adenovirus, was employed in HepG2 hepatocytes or C2C12 myotubes. We found that in the absence of AMPK activation, berberine still exhibited potent glucose-lowering and glycolysis-inducing effects on human hepatoma cells and mouse myotubes. For the first time, we demonstrated that berberine may promote glucose metabolism independently of AMPK pathway.

A parallel increase in glucose consumption and lactate release was observed in this study. The lactate in the culture medium is derived from glycolysis process. Glycolysis transfers energy from glucose to ATP through an oxygen-independent path outside mitochondria. Compared with aerobic respiration, glycolysis is less efficient in ATP synthesis and requires more glucose to produce the same amount of ATP [21]. Thus, glycolysis enhancement may be the primary mechanism by which berberine increase glucose consumption in hepatocytes and myotubes. Therefore, mitochondrial function was investigated to explore the role of respiratory modification in mediating the glucose-lowering effect of berberine.
The results from the current study indicate that berberine almost completely blocked electron transport train complex I activity. Our previous study revealed that berberine repress mitochondrial function in vitro [21]. Turner et al reported berberine suppressed respiration via complex I in isolated mitochondria [33]. However, it’s important to differentiate pharmaceutical effect from toxic effect of berberine in mitochondria. Thus, intact living cells cultured in a 24-well microplate and the best effective dosage of berberine (20 μmol/L) was chosen in the experiment. Extracellular flux analysis was performed to assess the mitochondrial respiration by Seahorse XF24 analyzer [34,35]. Complex I - linked respiration was nearly totally blocked by berberine. This is the first study in which respiratory chain complex I inhibition by berberine was observed in living cells. Unexpectedly, the cells grow normally and consuming much more glucose in the absence of complex I activity. The data challenged our concept about complex I inhibition of which may be a key to solve the disturbance of glucose metabolism.

Our results confirmed that berberine was able to inhibit ATP synthesis in C2C12 myotubes. In extracellular flux analysis, oligomycin reduced OCR, which represents the decreased ATP synthesis [26]. The reduction was nearly erased by berberine. The inhibition of ATP synthesis leads to compensatory enhancement of anaerobic respiration. The decrease of ATP production may elevate AMP/ATP ratio in cells, further leads to the activation of AMPK [36]. Therefore, mitochondrial inhibition might be the initial driving force for glucose-lowering action of berberine.

This study suggests that berberine and metformin may share similar effects and mechanisms in regulation of glucose metabolism. Our previous study showed the hypoglycemic efficacy of berberine was comparable to that of metformin in a clinical trial [4]. However, these two medications have never been compared in ex vivo experiments. This study explored underlying mechanism and pattern of glucose-lowering effect of berberine and metformin in cells. Except effective dose range (1~10 mmol/L for metformin and 5~40 μmol/L for berberine), berberine and metformin showed almost identical effects on stimulating glucose consumption and lactate release. For the first time, this study showed that these two medications had similar capacity to activate AMPK pathway and inhibit complex I activity. This indicates they may belong to the same class of hypoglycemic agents despite of totally different chemical structure.

This study also suggested that AMPK pathway may not play a central role in the action of metformin. Up to now, AMPK is still considered as the main target of metformin [37,38], although Foretz et al found that metformin was able to inhibit glucogenogenesis in AMPKα2-null mouse hepatocytes [39]. A recent paper reported that metformin blocked glucagon-dependent glucose output from hepatocytes by decreasing production of cyclic AMP [31]. Some scientists argued that results from mouse genetic model were not always applicable to human body since inactivation of critical enzymes sometimes led to adaptations in alternative pathways [40]. Thus, new strategy was implemented in this study. For the first time, effects of metformin on glucose consumption and glycolysis were studied in cell models of AMPK transient inactivation. Temporary blockade of AMPK failed to diminish the pharmaceutical effects of metformin, too. This study provides evidence that, in addition to inhibition of glucose production, AMPK may also be dispensable for metformin-induced glucose consumption and glycolysis in hepatocytes and myotubes.

In conclusion, the results from the current study demonstrated that berberine inhibited mitochondrial respiratory chain complex I, which led to the suppression of ATP synthesis, and the enhancement of glycolysis. The elevated glycolysis may be a primary cause for increased glucose consumption in hepatocytes and myotubes by berberine. Furthermore, all these effects are independent of AMPK activation. Berberine and metformin showed identical effects in vitro. We suggest complex I inhibition may replace AMPK activation as a major molecular mechanism of berberine and metformin.

**Supporting Information**

Figure S1 Berberine had no effects on complex II-linked respiration in C2C12 myotubes. To further understand the modulation of mitochondrial respiration by berberine, complex II-linked respiration was also examined by extracellular flux assay in C2C12 myotubes. After complex I-linked respiration was inhibited by rotenone, succinate was further administrated as the substrate for complex II. Then antimycin A was added to inhibit the function of complex III, which is the downstream of complex II. The change of OCR was recorded in real time. Since complex I had been already blocked, OCR reduction caused by antimycin A reflected complex II-linked respiration. As shown in Fig. S1, there was no significant change in complex II-linked respiration with the treatment of berberine or metformin. The results suggest that berberine and metformin had no effects on complex II activity. A: Traces of OCRs in control, berberine- or metformin-treated C2C12 cells followed the addition of rotenone, succinate and Antimycin A. B: Effects of berberine and metformin on complex II-linked oxygen consumption. OCRs are expressed as fold of baseline OCRs, and shown as means ± SEM, n = 3.
Acknowledgments

We thank Dr. Jia Li and Dr. Jingya Li for the kind gifts of DN-AMPK and Dr. Mingliang Zhang.

References

1. Yin J, Ye J, Jia W (2012) Effects and mechanisms of berberine in diabetes treatment. Acta Pharmacuetica Sinica 2: 327–334.
2. Yin J, Zhang H, Ye J (2008) Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 8: 99–111.
3. Zhang Y, Li X, Zou D, Liu W, Yang J, et al. (2008) Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2539–2565.
4. Yin J, Xing H, Ye J (2008) Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: 57: 712–717.
5. Hu Y, Ebih EA, Kittelbruut J, Ronan PJ, Munger K, et al. (2012) Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 19: 361–367.
6. Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY, et al. (2011) Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol 668: 467–471.
7. Yang QH, Hu SP, Zhang YP, Xie WN, Li N, et al. (2011) Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. Chin J Integr Med 17: 205–211.
8. Li H, Dong B, Park SW, Lee HS, Chen W, et al. (2009) Hepatotoxicity factor alpha plays a critical role in PCKS9 gene transcription and regulation by the natural hypolipidemic compound berberine. J Biol Chem 284: 28883–28895.
9. Singh AB, Li H, Kan CF, Dong B, Nicoll MR, et al. (2013) The Critical Role of mRNA Destabilizing Protein Heterogeneous Nuclear Ribonucleoprotein D in T Untranslated Region-Mediated Decay of Low-Density Lipoprotein Receptor mRNA in Liver Tissue. Arteriolecular Thromb Vasc Biol.
10. Wang LH, Li XL, Li Q, Yu Y, Hu HJ, et al. (2012) Berberine alleviates ischemic arrhythmias via recovering depressed Epo and I(Ca) currents in diabetic rats. Phytomedicine 19: 206–210.
11. Alliso F, Mecurizio V, Fazio V, Fazio S (2010) Cardiovascular and metabolic effects of Berberine. World J Cardiol 2: 71–77.
12. Brueg JM, Ancellin N, Groudi P, Guillard R, Martin S, et al. (2006) Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47: 1281–1288.
13. Lee YS, Kim WS, Kim KH, Yoon MJ, Choi HJ, et al. (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256–2264.
14. Choi BH, Aun IS, Kim YH, Park JW, Lee SY, et al. (2006) Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 38: 599–605.
15. Huang C, Zhang Y, Gong Z, Sheng X, Li Z, et al. (2006) Berberine inhibits ST3-L1 adipocyte differentiation through the PPARGamma pathway. Bioch Biophys Res Commun 338: 571–578.
16. Hwang CH, Wang CJ, Chou FP, Teng TH, Huich YS, et al. (2006) Inhibitory effect of berberine on tert-butyl hydroperoxide-induced oxidative damage in rat liver. Arch Toxicol 76: 664–670.
17. Jung HA, Yoon NY, Bae HJ, Min BS, Choi JS (2008) Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch Pharm Res 31: 1405–1412.
18. Liu W, Liu P, Tao S, Deng Y, Li X, et al. (2008) Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys 467: 129–134.
19. Cui G, Qiu X, Zhang X, Gong Z, Ge B, et al. (2009) Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 cell differentiation in type 1 diabetic mice. J Biol Chem 284: 28420–28429.
20. Viobliet B, Guigas B, Leclerc J, Hebrard S, Lantrier L, et al. (2009) AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 196: 81–90.
21. Yin J, Gao Z, Liu D, Liu Z, Ye J (2008) Berberine improves glucose metabolism through induction of glycogens. Am J Physiol Endocrinol Metab 294: E418–156.
22. Yin J, Hu R, Chen M, Tang J, Li F, et al. (2002) Effects of berberine on glucose metabolism in vitro. Metabolism 51: 1439–1443.
23. Yin J, Zuberi A, Gao Z, Liu D, Liu Z, et al. (2009) Shelainhua extract inhibits GS-3{beta} and promotes glucose metabolism. Am J Physiol Endocrinol Metab 296: E1275–1280.
24. Zhang LN, Xu L, Zhou HY, Wu LY, Li YY, et al. (2013) Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One 8: e72092.
25. Li YY, Yu LF, Zhang LN, Qin BY, Su MB, et al. (2013) Novel small-molecule AMPK activator orally exerts beneficial effects on diabetic db/db mice. Toxicol Appl Pharmacol 273: 325–334.
26. Abe Y, Sakairi T, Kajiyama H, Shirivastav S, Besson C, et al. (2010) Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol 299: C624–476.
27. Nicholls DG, Darley-Umary VM, Wu M, Jensen PB, Rogers GW, et al. (2010) Bioenergetic profile using C2C12 myoblast cells. J Vis Exp.
28. Yin J, Hu R, Chen M, Tang J, Li F, et al. (2003) In vitro research on the effects of berberine, oleandric acid and allidrin on glucose metabolism. Journal of Beijing University of TCM 26: 36–38.
29. Yin J, Hu R, Tang J, Li F, Chen M, et al. (2001) Glucose-lowering effect of berberine in vitro. Acta Universitatis Medicinae Shandong 21: 425–427.
30. Yin J, Hu R, Chen M, Tang J, Li F, et al. (2002) Comparison of glucose-consuming effect of metformin, troglitazone and berberine on HepG2 cells. Chinese Journal of Endocrinology and Metabolism 18: 488–489.
31. Miller RA, Chu Q, Xie J, Forrezt M, Viobliet B, et al. (2013) Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494: 256–260.
32. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, et al. (2009) Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296: E955–964.
33. Turner N, Li JY, Gosby A, To SW, Cheng Z, et al. (2008) Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57: 1414–1418.
34. Clerc F, Peltier BM (2012) Investigation of mitochondrial dysfunction by sequential microplate-based respiration measurements from intact and permeabilized neurons. PLoS One 7: e39465.
35. Bao J, Scott I, Lu Z, Pang L, Dimond CC, et al. (2010) SIRT3 is regulated by LKB1 mediates glucose homeostasis in liver and therapeutic effects of AMPK activator orally exerts beneficial effects in db/db mice. PLoS One 7: e39465.
36. Ohashi JS, Steel R, Chen ZP, Scott JW, Ling N, et al. (2011) AMPK is a direct adenylyl charge-regulated protein kinase. Science 332: 1433–1435.
37. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174.
38. Shaw RJ, Lamiia KA, Vasquez D, koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642–1646.
39. Forrezt M, Hebrard S, Leclerc J, Zarrinparshesh E, Soty M, et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2355–2369.
40. Rena G, Pearson ER, SAKAMOTO K (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56: 1896–1906.

Author Contributions

Conceived and designed the experiments: JY JW. Performed the experiments: MX YX JY WH XY LS. Analyzed the data: MX YX JY WH XY LS. Contributed reagents/materials/analysis tools: JW LW FL LS. Wrote the paper: MX YX JY LS LW.

PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e103702